
In 2013, the US Food and Drug Administration (FDA) approved a new class of drugs to treat patients with Type 2 diabetes. Invokana (also called canagliflozin) is a subtype 2 sodium-glucose transport inhibitor (SGLT2 inhibitor) that is used to treat this common condition. Other names for the drug include Invokamet and Invokamet XR. SGLT2 inhibitors […]